Previous 10 | Next 10 |
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced Chris Lowe, the company’s chief operating officer ...
Insider buying increased last week. Notable Insider Buys: Designer Brands Inc., Apartment Investment and Management Company, Cortexyme, Inc., Advantage Solutions Inc., and Limoneira Company. Notable Insider Sells: L Brands, Inc., Ulta Beauty, Inc., Facebook, Inc., Copart, Inc., an...
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced Casey Lynch, the company’s chief executive officer...
-- Presentation to be webcast on Cortexyme’s website -- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, today announced Chris Lowe, the company’s chief operating officer a...
-- Partnership with Parkinson Study Group Advisory Panel to collaborate on Parkinson’s Disease Program -- -- Presentation at AD/PD™ 2021 Underscores Relevance of Cortexyme’s Approach -- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmace...
Insider buying increased significantly last week. Notable Insider Buys: Enterprise Products Partners L.P., Teledyne Technologies Incorporated, Agree Realty Corporation, Cortexyme, Inc., and Kaleyra, Inc. Notable Insider Sells: Zoom Video Communications, Inc., Virgin Galactic Holdi...
The extension study of atuzaginstat has been put on hold by the FDA. The RCT is fully enrolled and no hold has been placed. The drop in price is an overreaction. For further details see: Cortexyme: The OLE Study Hold Does Not Matter
Yesterday, Cortexyme ([[CRTX]] +2.9%) recorded its sharpest one-day share price decline after the company announced a partial clinical hold on atuzaginstat (COR388), impacting the open-label extension phase of the ongoing GAIN Trial.Citing that to impact the trial outcome, Jefferies...
Gainers: Luokung Technology (LKCO) +112%.Kubient (KBNT) +63%.SOS (SOS) +58%.Torchlight Energy Resources (TRCH) +54%.Protective Insurance (PTVCB) +53%.500.com (WBAI) +45%.ALJ Regional (ALJJ) +45%.Urban Tea (MYT) +44%.Canaan (CAN) +36%.Applied Genetic Technologies (AGTC) +32...
Gainers: Diffusion Pharmaceuticals (DFFN) +36%, Strongbridge Biopharma (SBBP) +25%, KemPharm (KMPH) +20%, Senseonics Holdings (SENS) +17%, ReWalk Robotics (RWLK) +14%.Losers: bluebird bio (BLUE) -32%, Cortexyme (CRTX) -30%, Inhi...
News, Short Squeeze, Breakout and More Instantly...
New ticker symbol (Nasdaq: QNCX) to initiate trading on August 1, 2022 Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company’s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the cor...
Once daily dose of COR588 over 10-day period well-tolerated with no serious adverse events observed Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful ...
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company’s 3CLpro inhibitor, COR803, for treatment of coronavirus...